NCT02252055View on ClinicalTrials.gov

The ONE Study ATDC Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 19, 2015

Primary Completion Date

November 14, 2018

Study Completion Date

November 14, 2018

Conditions
Renal Failure, End Stage
Interventions
BIOLOGICAL

ATDC_Nantes

"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation into recipients also recipients of a living donor renal transplantation.~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus background immunosuppression ( as described in detail in the arm description)"

Trial Locations (1)

44093

Nantes University hospital, Nantes

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT02252055 - The ONE Study ATDC Trial | Biotech Hunter | Biotech Hunter